Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Determining the true incidence of seasonal respiratory syncytial virus-confirmed hospitalizations in preterm and term infants in Western Australia

Respiratory syncytial virus contributes to significant global infant morbidity and mortality. We applied a previously developed statistical prediction model incorporating pre-pandemic RSV testing data and hospital admission data to estimate infant RSV-hospitalizations by birth month and prematurity, focused on infants aged <1 year.

Research

Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges

Increases in invasive group A streptococcal disease (iGAS) have recently been reported in multiple countries in the northern hemisphere, occurring during, and outside of, typical spring peaks. We report the epidemiology of iGAS among children in Australia from 1 July 2018 to 31 December 2022.

Research

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal.

Research

Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study

The impact of pneumococcal conjugate vaccines (PCVs) on pneumonia in children is well-documented but data on 23-valent pneumococcal polysaccharide vaccine (PPV23) are lacking. Between 2001 and 2011, Indigenous children in Western Australia (WA) were recommended to receive PPV23 at 18-24 months of age following 3 doses of 7-valent PCV. We evaluated the incremental effectiveness of PPV23 against pneumonia hospitalisation.

Research

Invasive aspergillosis in adult patients in Australia and New Zealand: 2017–2020

New and emerging risks for invasive aspergillosis (IA) bring the need for contemporary analyses of the epidemiology and outcomes of IA, in order to improve clinical practice.

News & Events

RSV and influenza detections hit record low levels in 2020

Western Australia has experienced historically low levels of respiratory syncytial virus (RSV) and influenza this winter due to the public health measures implemented to prevent the spread of COVID-19.

News & Events

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

News & Events

Babies at risk due to delayed vaccinations

As many as a quarter of Australian babies aren’t getting vaccinated on time, leaving them at risk of developing life-threatening illnesses such as whooping cough when they are most vulnerable.

News & Events

Whooping cough vaccine could help in the fight against food allergies

A dose of the whooping cough vaccine might reduce cases of childhood food allergies according to latest research by the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia.

News & Events

Wesfarmers tops 2019 GivingLarge Report

The major funder of the Wesfarmers Centre of Vaccines and Infectious Diseases based at The Kids Research Institute Australia has been recognised as Australia’s most generous giver.